Last updated on September 2019

BHV3000-302: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy, Trial of BHV-3000 (rimegepant) for the Acute Treatment of Migraine

---

Brief description of study

BHV3000-302: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy, Trial of BHV-3000 (rimegepant) for the Acute Treatment of Migraine

 

Detailed Study Description

BHV-3000 versus placebo in Acute Migraine. The study will recruit male and female patients 18 years of age and older with at least a one-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorders, including an age of onset prior to 50, migraine attacks that last about 4 - 72 hours, not more than 8 attacks of moderate or severe intensity per month within the last 3 months and not less than 2 attacks per month.